Pi-Cardia’s ShortCut Leaflet Modification Technology Receives NTAP

August 6, 2025—Pi-Cardia Inc., an Israel-based developer of leaflet modification solutions for treating heart valves, announced that the Centers for Medicare & Medicaid Services (CMS) has approved a New Technology Add-On Payment (NTAP) for the company’s ShortCut device, effective October 1, 2025.

The company stated that the NTAP designation recognizes ShortCut as a breakthrough technology that addresses a critical unmet need in valve-in-valve transcatheter aortic valve replacement (TAVR) by enabling treatment for patients at risk of coronary obstruction.

According to Pi-Cardia, beginning in October, CMS will provide eligible hospitals with up to $9,750 in additional reimbursement per case when the ShortCut procedure is performed. This payment is in addition to the Medicare Severity Diagnosis Related Group—MS-DRG—amount for TAVR.

To receive the NTAP, hospitals must report ICD-10-PCS code X28F3VA, which specifically identifies leaflet splitting procedures performed with ShortCut, advised the company.

In March 2025, Pi-Cardia announced the first commercial procedures with the ShortCut device, which received FDA clearance in September 2024.